Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma

Biomedical Chromatography

Volumn 20, Issue 8, 2006, Pages 671-673

  Sparidans, Rolf W ^a   Dost, Frits ^a   Crommentuyn, Kristel M L ^b   Huitema, Alwin D R ^b   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Atazanavir; Liquid chromatography; Liquid liquid extraction; Protease inhibitor; Tipranavir

Indexed keywords

DICHLOROMETHANE; DISEASES; SOLVENT EXTRACTION; VIRUSES;

ATAZANAVIR; HUMAN IMMUNODEFICIENCY VIRUS; LIQUID CHROMATOGRAPHIC ASSAY; LIQUID-LIQUID EXTRACTION; PHASE LIQUIDS; PLASMA SAMPLES; PROTEASE INHIBITOR; REVERSED PHASE; REVERSED PHASE LIQUID-CHROMATOGRAPHY; TIPRANAVIR;

LIQUID CHROMATOGRAPHY;

ATAZANAVIR; COTRIMOXAZOLE; DICHLOROMETHANE; DIDANOSINE; LOPERAMIDE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; TIPRANAVIR;

ACCURACY; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG STRUCTURE; EVAPORATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INGESTION; LIQUID LIQUID EXTRACTION; MALE; REVERSED PHASE LIQUID CHROMATOGRAPHY; SAMPLE; ULTRAVIOLET RADIATION; VALIDATION STUDY;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33747023962     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.667     Document Type: Article

References (9)

1. Anonymous. Tipranavir gets approved. AIDS Patient Care STDS 2005; 19: 615.
2. Center for Drug Evaluation and Research of the US Department of Health and Human Services, Food and Drug Administration. Guidance for industry; Bioanalytical method validation. Available at: www.fda.gov/cder/guidance/4252fnl.htm, 2001 (accessed 30 November 2004).
3. Colombo S, Beguin A, Marzolini C, Telenti A, Biollaz J and Decosterd LA. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. Journal of Chromatography B: Analytical Technology and Biomedical Life Science 2006; 832: 138.
4. Crommentuyn KM, Rosing H, Hillebrand MJ, Huitema AD and Beijnen JH. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of Chromatography B: Analytical Technology and Biomedical Life Sciences 2004; 804: 359.
5. Croom KF and Keam SJ. Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 2005; 65: 1669.
6. Flexner C, Bate G and Kirkpatrick P. Tipranavir. Nature Review Drug Discovery 2005; 4: 955.
7. Giraud E, Rey E, Treluyer JM, Pons G and Jullien V. Quantification of tipranavir in human plasma by high-performance liquid chromatography with UV detection. Journal of Chromatography B: Analytical Technology Biomedical Life Science 2006; 830: 86.
8. Rosing H, Man WY, Doyle E, Bult A and Beijnen JH. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. Journal of Liquid Chromatography and Related Technology 2000; 23: 329.
9. Sparidans RW, Dost F, Crommentuyn KM, Huitema AD, Schellens JH and Beijnen JH. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomedical Chromatography 2006; 20: 72.